2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEnd of chemotherapyEquilibrium radionuclide angiographyBreast cancerAdjuvant therapySequential doxorubicinCardiac functionIpsilateral axillary lymph nodesHigh-risk breast cancerRisk breast cancerClinical heart failureInitiation of chemotherapyAxillary lymph nodesVentricular ejection fractionEnd of therapyLong-term cardiotoxicityMedian absolute changeEligible patientsFilgrastim supportLate cardiotoxicityAxillary nodesAsymptomatic declineEjection fractionHeart failureLymph nodes
2000
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function
Rose M, Lee F, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness B. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-139. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDoxorubicinFemaleFollow-Up StudiesHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMiddle AgedNeutropeniaPaclitaxelStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsLeft ventricular ejection fractionHigh-dose chemotherapyBreast cancer patientsMean absolute decreaseCancer patientsAbsolute decreaseLV functionCell rescueImpaired left ventricular functionHigh-dose thiotepaImpaired LV functionHigh-dose melphalanStem cell rescueSymptomatic heart failureCourses of chemotherapyVentricular ejection fractionLeft ventricular functionSequential paclitaxelMetastatic diseaseCardiac deathCardiac symptomsEjection fractionHeart failureVentricular functionCardiac toxicity
1995
Introduction
Elefteriades J, Lee F, Letsou G. Introduction. Cardiology Clinics 1995, 13: 1-3. PMID: 7796423, DOI: 10.1016/s0733-8651(18)30057-2.Peer-Reviewed Original ResearchConceptsSevere left ventricular dysfunctionLeft ventricular ejection fractionAutomatic defibrillator implantationCoronary bypass surgeryLeft ventricular dysfunctionVentricular ejection fractionSpecific patient groupsAdvanced treatment modalitiesHeart transplantationVentricular aneurysmectomyVentricular dysfunctionBypass surgeryDefibrillator implantationValve replacementEjection fractionCardiology clinicPatient groupTreatment modalitiesClinical studiesLeft ventricleTraditional modalitiesModalitiesAneurysmectomyPatientsSurgery
1994
Circadian variation of sustained ventricular tachycardia in patients with coronary artery disease and implantable cardioverter-defibrillators.
Lampert R, Rosenfeld L, Batsford W, Lee F, McPherson C. Circadian variation of sustained ventricular tachycardia in patients with coronary artery disease and implantable cardioverter-defibrillators. Circulation 1994, 90: 241-247. PMID: 8026004, DOI: 10.1161/01.cir.90.1.241.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseSustained ventricular tachycardiaVentricular tachycardiaArtery diseaseCircadian variationVT occurrenceSudden deathMechanism of VTLife-threatening ventricular tachycardiaEpisodes of VTAmbulatory ECG monitoringConsecutive patientsEjection fractionDrug therapyIndividual patientsEpidemiological dataPatientsTachycardiaECG monitoringCircadian patternDiseaseArrhythmiasDeathInfrequent eventEpisodes